Clinical Trials Sponsored by Immodulon Therapeutics Ltd

Total 462 results

Immodulon Therapeutics Ltd

Completed

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Metastatic Colorectal Cancer

United Kingdom
Immodulon Therapeutics Ltd

Completed

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

Spain, United Kingdom, Italy, Cyprus, Ireland
Immodulon Therapeutics Ltd

Completed

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Melanoma

United Kingdom
Immodulon Therapeutics Ltd

Terminated

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Malignant Melanoma

United Kingdom
Immodulon Therapeutics Ltd

Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

Metastatic Cancer

France, United Kingdom
Immodulon Therapeutics Ltd
Theradex; HCA International Limited

Completed

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Melanoma

United Kingdom
Impatients N.V. trading as myTomorrows
Immodulon Therapeutics Ltd

No longer available

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Stage IV | Pancreas Cancer | Pancreatic Cancer Stage III

France, United Kingdom
AIO-Studien-gGmbH
Roche Pharma AG; Immodulon Therapeutics Ltd

Recruiting

Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO)

Colorectal Cancer

Germany
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Apollo Therapeutics Ltd

Recruiting

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Dermatitis | Eczema | Atopic Dermatitis | Atopic | Eczema, Atopic | Dermatologic Disease | Eczema Atopic Dermatitis

United States, Canada
NeuroSense Therapeutics Ltd.

Recruiting

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. (RoAD)

Alzheimer Disease

Israel
Iksuda Therapeutics Ltd.

Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

Breast Cancer | Gastric Cancer | Gastroesophageal-junction Cancer

Australia
Amber Therapeutics Ltd

Not yet recruiting

AURA 1: Augmenting Urinary Reflex Activity: Study 1 (AURA1)

Overactive Bladder | Urge Incontinence
Enlivex Therapeutics Ltd.

Not yet recruiting

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Covid19
Raziel Therapeutics Ltd.

Completed

RZL-012 for Dercum's Disease Lipomas

Dercum's Disease Lipomas

United States
Raziel Therapeutics Ltd.

Completed

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Flank Mass

United States
Raziel Therapeutics Ltd.

Completed

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Submental Fat

United States
Nerre Therapeutics Ltd.

Completed

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Chronic Refractory Cough

United States, Canada, United Kingdom
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Prescient Therapeutics, Ltd.

Terminated

PTX-200 and Carboplatin in Ovarian Cancer

Ovarian Cancer

United States
Nerre Therapeutics Ltd.

Completed

Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects

Healthy

United Kingdom
Enlivex Therapeutics Ltd.

Completed

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS (P-SOFA-1)

Organ Dysfunction Syndrome Sepsis

Israel
TauRx Therapeutics Ltd

Completed

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Behavioral Variant Frontotemporal Dementia (bvFTD)

United States, Australia, Canada, Croatia, Poland, Netherlands, United Kingdom, Spain, Germany, Italy, Romania, Singapore
PhytoTech Therapeutics, Ltd.

Completed

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Healthy Volunteers

Israel
TauRx Therapeutics Ltd

Terminated

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Alzheimer's Disease

Germany, United Kingdom
Chronos Therapeutics Ltd

Completed

A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Ark Therapeutics Ltd

Terminated

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence (AdV-VANTAGE)

End Stage Renal Disease

United States
TauRx Therapeutics Ltd

Completed

TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

Dementia, Alzheimer Type
CMP Therapeutics Ltd

Completed

Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis

Seasonal Allergic Rhinitis
STORM Therapeutics LTD

Recruiting

Oral Administration of STC-15 in Subjects With Advanced Malignancies

Cancer | Advanced Solid Tumor | Advanced Cancer

United States
Bioceltech Therapeutics, Ltd.

Recruiting

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

T Cell Lymphoblastic Lymphoma

China
Minovia Therapeutics Ltd.

Not yet recruiting

A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

Primary Mitochondrial Diseases

Israel
Ella Therapeutics Ltd

Recruiting

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Unresectable Melanoma | NSCLC Stage IV | Melanoma Stage IV

Israel
Minovia Therapeutics Ltd.

Recruiting

Collection of Placenta for Mitochondria Isolation

Pregnancy Related

Israel
Amber Therapeutics Ltd

Active, not recruiting

AURA-2: Augmenting Urinary Reflex Activity (AURA-2)

Overactive Bladder | Urge Incontinence

Belgium
Raziel Therapeutics Ltd.

Completed

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Submental Fat

United States
NeuroSense Therapeutics Ltd.

Active, not recruiting

A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PARADIGM)

Amyotrophic Lateral Sclerosis | ALS

Israel, Italy, Canada
Raziel Therapeutics Ltd.

Completed

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Submental Fat

United States
Apollo Therapeutics Ltd

Terminated

A Study to Evaluate Camoteskimab in Participants With Still's Disease

Adult Onset Still's Disease

United States, Belgium, Poland, Ukraine
TauRx Therapeutics Ltd

Terminated

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Alzheimer's Disease | Behavioral Variant Frontotemporal Dementia

Korea, Republic of, United States, Spain, Taiwan, Canada, Belgium, Malaysia, United Kingdom, Australia, Singapore, Croatia, Finland, France, Germany, Netherlands, Romania, Russian Federation
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

Healthy

United Kingdom
PsiOxus Therapeutics Ltd

Completed

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients (OCTAVE)

Recurrent Platinum Resistant Ovarian Cancer

United Kingdom, Spain
PsiOxus Therapeutics Ltd

Completed

Mechanism of Action Trial of ColoAd1 (MOA)

Resectable Colon Cancer | Resectable Non-small Cell Lung Cancer | Resectable Bladder Cancer | Resectable Renal Cell Carcinoma

Spain
Vensica Therapeutics Ltd.

Completed

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

Overactive Bladder

Czechia, Portugal
Celleron Therapeutics Ltd.

Unknown

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer (CAROSELL)

Colorectal Neoplasms Malignant

United Kingdom
SpotOn Therapeutics Ltd.

Suspended

Spoton Trial Evaluating the Efficacy on BAlance Disorder sYmptoms (STEADY) (STEADY)

Balance Disorders

Israel
Nerre Therapeutics Ltd.

Completed

A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers

Pharmacokinetic Study in Healthy Male Volunteers

United Kingdom
PhytoTech Therapeutics, Ltd.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

Epilepsy Intractable

Israel
Bioceltech Therapeutics, Ltd.

Unknown

CD19-CAR-T Cells in Patients With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
TauRx Therapeutics Ltd

Completed

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, United States, Spain, United Kingdom, Taiwan, Poland, Malaysia, Singapore, Canada, Croatia, Italy, Australia, Germany, Romania, Russian Federation, Bulgaria

3

Subscribe